Compile Data Set for Download or QSAR
Report error Found 284 Enz. Inhib. hit(s) with all data for entry = 1171
TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311957(US10166214, Example 93 | US9789082, Example 93 | U...)
Affinity DataEC50:  0.100nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311970(US10166214, Example 106 | US10675268, Example 106)
Affinity DataEC50:  0.100nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US9789082, Example 107 |...)
Affinity DataEC50:  0.200nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311973(US10166214, Example 109 | US10675268, Example 109)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312007(US10166214, Example 143 | US10675268, Example 143)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311944(US10166214, Example 80 | US9789082, Example 80 | U...)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311994(US10166214, Example 130 | US10675268, Example 130)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311967(US10166214, Example 103 | US10675268, Example 103)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311956(US10166214, Example 92 | US10675268, Example 92)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311990(US10166214, Example 126 | US9789082, Example 126 |...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081055(CHEMBL3421843 | US10166214, Example 49 | US9789082...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311992(US10166214, Example 128 | US9789082, Example 128 |...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081058(CHEMBL3421842 | US10166214, Example 22 | US9789082...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311969(US10166214, Example 105 | US10675268, Example 105)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312048(US10166214, Example 184 | US10675268, Example 184)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311939(US10166214, Example 75 | US10675268, Example 75)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311941(US10166214, Example 77 | US10675268, Example 77)
Affinity DataEC50:  0.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311888(US10166214, Example 24 | US9789082, Example 24 | U...)
Affinity DataEC50:  0.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312004(US10166214, Example 140 | US10675268, Example 140)
Affinity DataEC50:  0.600nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311876(US10166214, Example 12 | US10675268, Example 12)
Affinity DataEC50:  0.600nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311946(US10166214, Example 82 | BDBM311964 | US10675268, ...)
Affinity DataEC50:  0.600nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312015(US10166214, Example 151 | US10675268, Example 151)
Affinity DataEC50:  0.600nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311974(US10166214, Example 110 | US10675268, Example 110)
Affinity DataEC50:  0.700nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311885(US10166214, Example 21 | US9789082, Example 21 | U...)
Affinity DataEC50:  0.700nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311940(US10166214, Example 76 | US10675268, Example 76)
Affinity DataEC50:  0.800nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312022(US10166214, Example 158 | US10675268, Example 158)
Affinity DataEC50:  0.800nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312001(US10166214, Example 137 | US10675268, Example 137)
Affinity DataEC50:  0.800nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311952(US10166214, Example 88 | US10675268, Example 88)
Affinity DataEC50:  0.800nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312009(US10166214, Example 145 | US10675268, Example 145)
Affinity DataEC50:  0.900nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312014(US10166214, Example 150 | US10675268, Example 150)
Affinity DataEC50:  0.900nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311881(US10166214, Example 17 | US10675268, Example 17)
Affinity DataEC50:  1nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312013(US10166214, Example 149 | US10675268, Example 149)
Affinity DataEC50:  1nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312012(US10166214, Example 148 | US9789082, Example 148 |...)
Affinity DataEC50:  1.10nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311909(US10166214, Example 45 | US10675268, Example 45)
Affinity DataEC50:  1.20nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312040(US10166214, Example 176 | US10675268, Example 176)
Affinity DataEC50:  1.20nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311944(US10166214, Example 80 | US9789082, Example 80 | U...)
Affinity DataKi:  1.20nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081060(CHEMBL3421844 | US10166214, Example 101 | US978908...)
Affinity DataEC50:  1.20nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311954(US10166214, Example 90 | US10675268, Example 90)
Affinity DataEC50:  1.40nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311987(US10166214, Example 123 | US10675268, Example 123)
Affinity DataEC50:  1.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311958(US10166214, Example 94 | US9789082, Example 94 | U...)
Affinity DataEC50:  1.60nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM312017(US10166214, Example 153 | US10675268, Example 153)
Affinity DataEC50:  1.60nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311938(US10166214, Example 74 | US10675268, Example 74)
Affinity DataEC50:  1.60nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311968(US10166214, Example 104 | US10675268, Example 104)
Affinity DataEC50:  1.70nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311895(US10166214, Example 31 | US10675268, Example 31)
Affinity DataEC50:  1.90nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311984(US10166214, Example 120 | US10675268, Example 120)
Affinity DataEC50:  1.90nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311928(US10166214, Example 64 | US10675268, Example 64)
Affinity DataEC50:  2nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311978(US10166214, Example 114 | US10166214, Example 115 ...)
Affinity DataEC50:  2.10nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311966(US10166214, Example 102 | US10675268, Example 102)
Affinity DataEC50:  2.30nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311877(US10166214, Example 13 | US10675268, Example 13)
Affinity DataEC50:  2.40nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

TargetSomatostatin receptor type 4(Human)
Centrexion Therapeutics

US Patent
LigandPNGBDBM311916(US10166214, Example 52 | US10675268, Example 52)
Affinity DataEC50:  2.40nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
US Patent

Displayed 1 to 50 (of 284 total ) | Next | Last >>
Jump to: